Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00254462 · ClinicalTrials.gov registry record · Phase 4
Atomoxetine for Treating Attention Deficit Hyperactivity Disorder in Young Children
A Phase 4 study of Attention Deficit Disorder With Hyperactivity, sponsored by University of Nebraska.
- Completed
- Registry status
- Phase 4
- Development phase
- 93
- Enrollment target
- 3
- Study locations
NCT00254462 is a Phase 4 study of Attention Deficit Disorder With Hyperactivity that has completed, run by University of Nebraska. The registered enrollment target is 93 participants, below the 351-participant average among 20 other Attention Deficit Disorder With Hyperactivity trials with a reported enrollment target (74% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT00254462, a Phase 4 study of Attention Deficit Disorder With Hyperactivity, has completed, sponsored by University of Nebraska.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 93 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study will evaluate the effectiveness of atomoxetine in reducing the symptoms of attention deficit hyperactivity disorder (ADHD) in young children.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Atomoxetine
- BEHAVIORAL Parent Training
Study Locations (3)
Nebraska
- University of Nebraska Medical Center - Omaha
New York
- New York State Psychiatric Institute - New York
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2005-10-01 |
| Est. Completion | 2008-09-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00254462
The ClinicalTrials.gov registry entry for NCT00254462 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 93 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 351-participant average among 20 other Attention Deficit Disorder With Hyperactivity trials with a reported enrollment target (74% lower). The listed sponsor is University of Nebraska, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Attention Deficit Disorder With Hyperactivity appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT00254462 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Nebraska, New York, North Carolina.
Frequently Asked Questions
What is clinical trial NCT00254462 about?
NCT00254462 is a clinical study titled "Atomoxetine for Treating Attention Deficit Hyperactivity Disorder in Young Children". This study will evaluate the effectiveness of atomoxetine in reducing the symptoms of attention deficit hyperactivity disorder (ADHD) in young children.
What is the current status of trial NCT00254462?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 93 participants. The study started on 2005-10-01. Estimated completion is 2008-09-01.
What conditions does trial NCT00254462 study?
This clinical trial studies the following conditions: Attention Deficit Disorder With Hyperactivity.
What interventions are being tested in trial NCT00254462?
The interventions under investigation include: Placebo (DRUG), Atomoxetine (DRUG), Parent Training (BEHAVIORAL).
Who is sponsoring clinical trial NCT00254462?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00254462 being conducted?
This trial has 3 study locations across Nebraska, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Attention Deficit Disorder With Hyperactivity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Home-based Transcranial Direct Current Stimulation (tDCS) for Treatment of Attention-deficit/Hyperactivity Disorder (ADHD)
RECRUITING · NA
-
Brain Imaging of Childhood Onset Psychiatric Disorders, Endocrine Disorders and Healthy Volunteers
ACTIVE NOT RECRUITING
-
Efficacy and Safety of NFC-1 in Adolescents With Genetic Disorders Impacting mGluR and ADHD
COMPLETED · Phase 2
-
Behavioral Treatment, Drug Treatment, and Combined Treatment for Attention Deficit Hyperactivity Disorder (ADHD)
COMPLETED · NA
-
TRI102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)
COMPLETED · Phase 3
-
Atomoxetine for Treating Cocaine Abuse in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.